At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 80 enrolled
Drug / intervention
HerpV and QS-21 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2a, Multicenter, Double-blinded, Randomized, 2-Period Trial to Evaluate the Effect of HerpV Administered in Combination With the Stimulon® Adjuvant QS-21 on Viral Shedding in Adults With Recurrent Genital Herpes
In Brief
A Phase 2 clinical trial evaluating HerpV and QS-21 and Placebo for Herpes Simplex Type 2. Completed, enrolled 80 participants across 5 sites.
Detailed Summary
The purpose of this study is to evaluate the effect of recombinant human heat shock protein 70-polyvalent peptide complex (HerpV) vaccine administration on recurring episodes of genital herpes by evaluating viral shedding before and after treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHerpes Simplex Type 2
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedSep 2012
Enrollment StartOct 2012
Primary CompletionSep 2013
Study CompletionJan 2015
TodayJul 2026
First PostedSep 19, 2012
Enrollment StartOct 29, 2012
Primary CompletionSep 1, 2013
Study CompletionJan 1, 2015
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 13.8 years ago
Interventions
HerpV and QS-21drug
HerpV (recombinant human heat shock protein 70 \[rh-Hsc70\] polyvalent peptide complex) in combination with adjuvant QS-21
Placebodrug
phosphate buffered saline